HedgePath Pharmaceuticals discovers, develops and commercializes therapeutics for the treatment of cancer... Read more
HedgePath Pharmaceuticals discovers, develops and commercializes therapeutics for the treatment of cancer... Read more
News
Mar 28, 2025
Marketscreener
Inhibitor Therapeutics: Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
Aug 22, 2024
centralcharts
Press Release: Inhibitor Therapeutics : Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan
Aug 06, 2024
Marketscreener
Inhibitor Therapeutics: Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
Mar 29, 2024
Marketscreener
Inhibitor Therapeutics: Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Dec 19, 2023
centralcharts
Press Release: Inhibitor Therapeutics : Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
Dec 13, 2023
centralcharts
Press Release: Inhibitor Therapeutics : Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
Sep 16, 2022
MarketScreener
Inhibitor Therapeutics: Inhibitor Therapeutics : NOTICE OF PENDENCY OF DERIVATIVE AND CLASS ACTIONS, PROPOSED SETTLEMENT AND SETTLEMENT HEARING - Form 8-K
Sep 09, 2022
Law 360
Inhibitor Therapeutics: Florida Pharma Co. Settles Drug Control Suit For $14.25M
Oct 12, 2020
Zolmax News
Hedgepath Pharmaceuticals: Inhibitor Therapeutics (OTCMKTS:INTI) versus Bioanalytical Systems (OTCMKTS:BASI) Head to Head Review
May 06, 2020
sec
Hedgepath Pharmaceuticals: Inhibitor Therapeutics, Inc.received a Paycheck Protection Program loan
